Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis

Journal of Medical Economics

Volumn 13, Issue 3, 2010, Pages 381-392

  Borgström, Fredrik ^a,b   Ström, Oskar ^a,b   Marin, Fernando ^c   Kutahov, Alexey ^c   Ljunggren, Östen ^d  

^a i3 Innovus ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ELI LILLY AND COMPANY   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

cost effectiveness; osteoporosis; parathyroid hormone; teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SWEDEN;

AGED; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; FRACTURES, BONE; HUMANS; MARKOV CHAINS; MULTICENTER STUDIES AS TOPIC; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; QUALITY-ADJUSTED LIFE YEARS; SWEDEN; TERIPARATIDE;

EID: 77956686262     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.499072     Document Type: Article

References (53)

1. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
2. Delmas PD, Marin F, Marcus R, et al. Beyond hip: importance of other nonspinal fractures. Am J Med 2007;120:381-387
3. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767
4. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26: 688-703
5. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
6. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-339
7. Lundkvist J, Johnell O, Cooper C, et al. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 2006;17:201-211
8. General guidelines for economic evaluations from the Pharmaceutical Benefits Board. (LFNAR 2003:2) [cited 2007 2007-05-12]. 2003; Available from http://www.lfn.se/LFNTemplates/Page442.aspx
9. Borgstrom F, Jonsson B, Strom O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006;17:1781-1793
10. Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003;21:305-314
11. TreeAge Pro 2007. User Manual TreeAge software inc 2007
12. Rajzbaum G, Jakob F, Karras D, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008;24:377-384
13. o) in Sweden. Osteoporos Int 2006;17:S71-72
14. Behandling av Osteoporos -Rekommendationer. Lakemedelsverket (Medical Product Agency) [cited 2007-07-03]. 2007; Available from: http://www. lakemedelsverket.se/upload/Halso-%20och%20sjukvard/behandlingsrek/ osteoporos2007.pdf
15. Lindsay R, ScheeleWH, NeerR, et al.Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-2030
16. Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507-1513
17. Zethraeus N, Strom O, Borgstrom F. What is the risk of institutionalization after hip fracture? Osteoporos Int 2006;17:57-58
18. Weycker D, Macarios D, Edelsberg J, et al.Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-1652
19. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000;11:669-674
20. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention resholds. Osteoporos Int 2001; 12:417-427
21. Melton III LJ, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999;9:29-37
22. De Laet CE, van Hout BA, Burger H, et al.Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997;315:221-225
23. Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004;15:175-179
24. Statistics Sweden. Swedeiis Statistical Databases [cited 2007-05-30]. 2007; Available from: http://www.scb.se/eng/databaser/ssd.asp
25. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-561
26. Center JR, Nguyen TV, Schneider D, et al. after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353:878-882
27. Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137: 1001-1005
28. Jalava T, Sarna S, Pylkkanen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 2003; 18:1254-1260
29. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;15:108-112
30. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38-42
31. Poor G, Atkinson EJ, O'Fallon WM, et al. Determinants of reduced survival following hip fractures in men. Clin Orthop 1995;319:260-265
32. Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health 1991;105:443-446
33. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468-473
34. Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004;15:20-26
35. Average Exchange Rates. Sveriges Riksbank [cited 2007-09-15]. 2007; Available from: http://www.riksbanken.com
36. Farmaceutiska Specialiteter i Sverige (FASS). [cited 2007-10-31]. 2009; Available from: www.fass.se
37. Summary of Product Characteristics. [cited 2007-12-01]. 2007; Available from: www.emea.europa.eu/humandocs/PDFs/EPAR/preotact/H-659-PI-en.pdf
38. Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006;17: 637-650
39. Strom O, Borgstrom F, Zethraeus N, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 2008;79: 269-280
40. Jonsson B, Christiansen C, Johnell O, et al. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 1996; 103:30-38 (Pubitemid 126716948)
41. Stockholmsstads budgetavrakning 2003 [online]. [cited 2004-12-20]. 2009; Available from: www.stockholm.se/files/71600-71699/file-71645.pdf
42. Borgstrom F, Strom O. Long-term hip fracture costs related to institutionalization. Osteoporos Int 2007;18(Suppl 1):S1-192
43. Osteoporos Int 2007; 18:S1-192
44. Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166:1209-1217
45. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64
46. Burstrom K, Johannesson M, Diderichsen F. population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621-635
47. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316:736-741
48. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-340
49. The National Centre for Priority Setting in Health Care (PrioriteringsCentrum). Nationell model for oppna vertikala prioriteringar inom svensk halso-och sjukvard. PrioriteringsCentrum 2007;1
50. Sutton A, Ades AE, Cooper N, et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26:753-767
51. Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2009;20:625-630
52. Adachi JD, Hanley DA, Lorraine JK, et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 2007;29:2055-2067
53. Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006;17:1626-1629